Short Interest Report: CLINUVEL PHARM ADR (OTCMKTS:CLVLY) Sellers Increased By 1633.33% Their Shorts

November 29, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest Report: CLINUVEL PHARM ADR (OTCMKTS:CLVLY) Sellers Increased By 1633.33% Their Shorts

The stock of CLINUVEL PHARM ADR (OTCMKTS:CLVLY) registered an increase of 1633.33% in short interest. CLVLY’s total short interest was 10,400 shares in November as published by FINRA. Its up 1633.33% from 600 shares, reported previously. With 24,400 shares average volume, it will take short sellers 0 days to cover their CLVLY’s short positions. About 14,461 shares traded hands or 26.51% up from the average. Clinuvel Pharmaceuticals Ltd (ADR) (OTCMKTS:CLVLY) has risen 77.81% since April 26, 2016 and is uptrending. It has outperformed by 72.55% the S&P500.

Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The company has a market cap of $286.97 million. The Firm is focused on developing drugs for the treatment of a range of severe skin disorders. It currently has negative earnings. The Company’s lead compound, SCENESSE , prevents phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP).

CLVLY Company Profile

Clinuvel Pharmaceuticals Limited, incorporated on December 14, 1999, is a biopharmaceutical company. The Firm is focused on developing drugs for the treatment of a range of severe skin disorders. The Company’s lead compound, SCENESSE (afamelanotide 16 milligrams), prevents phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Firm focuses at preventing the symptoms of skin diseases related to the exposure to harmful ultra violet (UV) radiation and at repigmentation of the skin due to a number of depigmentation disorders. SCENESSE has completed Phase II and III trials in the United States and Europe, and has been granted marketing authorization by the European Commission for adults with EPP. It has activities in Europe, the United States and Singapore.

More notable recent Clinuvel Pharmaceuticals Ltd (ADR) (OTCMKTS:CLVLY) news were published by: Seekingalpha.com which released: “Scenesse Approval Increases Clinuvel’s Credibility” on October 24, 2014, also Seekingalpha.com with their article: “A Change In Retrophin Might Be Relevant For Clinuvel” published on October 01, 2014, Reuters.com published: “Clinuvel Pharmaceuticals agrees with FDA on new drug application timelines” on November 09, 2016. More interesting news about Clinuvel Pharmaceuticals Ltd (ADR) (OTCMKTS:CLVLY) were released by: Reuters.com and their article: “Clinuvel Pharmaceuticals agrees with FDA on new drug application timelines” published on November 08, 2016 as well as Reuters.com‘s news article titled: “Clinuvel Pharmaceuticals says FDA accepts Scenesse clinical data package for NDA submission” with publication date: July 18, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>